The key trends for increase in market, by public health organization are the growing expenditure on drugs and medical devices by public health organizations, steps by the government to build up strong analytical testing abilities, increasing number of drug approvals and clinical trials, and rising demand for specialized analytical testing services.
[68 Pages Report] The global analytical laboratory services market, by public health organization is projected to reach USD 333.8 Million by 2021 from USD 202.8 Million in 2016, at a CAGR of around 10.5% during the forecast period.
The overall market, by public health organization is positively impacted by factors such as the growing expenditure on drugs and medical devices by public health organizations, government initiatives to strengthen analytical testing capabilities, increasing number of drug approvals & clinical trials, and rising demand for specialized analytical testing services.
Market Dynamics
- Growing Expenditure on Drugs and Medical Devices By Public Organizations
- Government Initiatives to Strengthen Analytical Testing Capabilities
- Increasing Number of Drug Approvals and Clinical Trials
- Rising Demand for Specialized Analytical Testing Services
On the basis of type of service, the spend assessment is segmented into eight segments, namely, bioanalytical testing, batch release testing, stability testing, raw material testing, physical characterization, method validation, microbial testing, and environmental monitoring.
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=65590498
This growth can be attributed to factors such as the usage and development of a large number of macromolecules and Biosimilars for various therapeutic areas and the growing biopharmaceutical industry across the globe. The spending on batch release testing services is expected to account for the second largest share during the forecast period.
The geographical regions mapped in the report are:
Geographically, the market, by public health organization is segmented into North America, Europe, Asia-Pacific, and the Rest of the World (RoW). In 2015, North America commanded the largest share, followed by Europe, Asia-Pacific, and the RoW. The major share of this region can be attributed to the high expenditure on quality testing, strong regulatory scenario, increasing number of clinical trials, and the well-established federal testing laboratories in the region. Moreover, Asia-Pacific is expected to grow at the highest CAGR during the forecast period.
Request for sample pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=65590498
Some key players mentioned in the research report are:
Food and Drug Administration (U.S.), European Medicines Agency (U.K.), Federal Institute for Drugs and Medical Devices (Germany), Agence française de sécurité sanitaire des produits de santé (France), Agenzia Italiana del Farmaco (OTCPK:OTCPK:ITALY), the Spanish Medicines and Health Products Agency (Spain), Central Drugs Standard Control Organization (India), China Food and Drug Administration, and Pharmaceuticals and Medical Devices Agency (Japan).
